Zoetis Stock: 3 Key Investing Lessons from 2013
Will new developments from Novartis, Merck, and Eli Lilly threaten Zoetis’ dominance of the animal health business? What 3 key lessons should investors learn from Zoetis’ performance throughout 2013 since it was spun off from Pfizer?
5 Blockbuster Drugs Going Off Patent in 2014
Teva Pharmaceutical, Eli Lilly, Novartis, and AstraZeneca will lose patent exclusivity for five blockbuster drugs in 2014. Let’s take a closer look at what the future holds for these four companies.
Repros Poised to Take On Growing Testosterone Market
Repros wins meeting with FDA for oral testosterone frontrunner Androxal after FDA concerns last month tanked shares
Merck Faces Off Against Bristol-Myers' Yervoy
A compelling new drug in development from Merck (MRK) has a chance to change melanoma treatment, posing a threat to rapidly growing market share for Bristol Myers' (BMY) Yervoy.